Skip to main content
Advertisement
Browse Subject Areas
?

Click through the PLOS taxonomy to find articles in your field.

For more information about PLOS Subject Areas, click here.

  • Loading metrics

Correction: Inhibition of the Growth Factor MDK/Midkine by a Novel Small Molecule Compound to Treat Non-Small Cell Lung Cancer

  • Huifang Hao,
  • Yutaka Maeda,
  • Takuya Fukazawa,
  • Tomoki Yamatsuji,
  • Munenori Takaoka,
  • Xiao-Hong Bao,
  • Junji Matsuoka,
  • Tatsuo Okui,
  • Tsuyoshi Shimo,
  • Nagio Takigawa,
  • Yasuko Tomono,
  • Motowo Nakajima,
  • Iris M. Fink-Baldauf,
  • Sandra Nelson,
  • William Seibel,
  • Ruben Papoian,
  • Jeffrey A. Whitsett,
  •  [ ... ],
  • Yoshio Naomoto
  • [ view all ]
  • [ view less ]
  • Article
  • Metrics
  • Comments
  • Media Coverage

In Fig 5, the beta-actin is incorrect in panel B. Please see the correct Fig 5 here.

thumbnail
Fig 5. iMDK inhibited the PI3K/AKT pathway and influenced the apoptosis pathway.

A. Dose-dependently, phosphorylation of PI3K and AKT and the expression of survivin and XIAP, anti-apoptotic factors, were decreased while the expression of BAD, a pro-apoptotic factor, was increased 48 hours after treatment with iMDK. Shown is immunoblot performed as described in Methods. B. Time-dependently, phosphorylation of PI3K and AKT and the expression of survivin and XIAP were decreased while the expression of BAD was increased by treatment with iMDK at a concentration of 50 nM. Immunoblot was performed as described in Methods.

https://doi.org/10.1371/journal.pone.0307052.g001

Reference

  1. 1. Hao H, Maeda Y, Fukazawa T, Yamatsuji T, Takaoka M, Bao X-H, et al. (2013) Inhibition of the Growth Factor MDK/Midkine by a Novel Small Molecule Compound to Treat Non-Small Cell Lung Cancer. PLoS ONE 8(8): e71093. pmid:23976985